Baricitinib
-Baricitinib is a medication used in the treatment of certain autoimmune conditions, particularly rheumatoid arthritis. Baricitinib is an oral Janus kinase (JAK) inhibitor that works by targeting and inhibiting specific enzymes involved in the inflammatory process. It is commonly prescribed for the management of autoimmune diseases, such as rheumatoid arthritis, where the immune system mistakenly attacks the body's own tissues. -Baricitinib belongs to a class of drugs called DMARDs, JAK Inhibitors.-Baricitinib is indicated for the treatment of moderate to severe rheumatoid arthritis in adult patients who have not responded well to conventional disease-modifying antirheumatic drugs (DMARDs). -BARICITINIB (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
-The recommended dosage of Baricitinib may vary depending on the specific condition being treated. Typically, it is administered orally once daily, with or without food. Dosage adjustments may be made based on the patient's response and any adverse reactions. -oral; 2mg once daily
-Baricitinib is contraindicated in individuals with known hypersensitivity to the drug. It should not be used in combination with certain other medications, and caution should be exercised in patients with certain pre-existing conditions. - Hypersensitivity
-Baricitinib may increase the risk of serious infections, so caution is needed, especially in patients with a history of chronic or recurrent infections. -Monitoring for changes in blood cell counts, liver enzymes, and lipid levels is recommended during treatment. -Patients should be screened for tuberculosis prior to initiation of treatment. -Baricitinib increases the risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants (e.g., methotrexate, corticosteroids), Closely monitor for developing signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative for latent TB before initiating baricitinib. Avoid use of live vaccines with BARICITINIB. Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient Lactation: Breast feeding is not recommended Elderly: No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
-Common side effects of Baricitinib may include upper respiratory tract infections, hypertension, increased levels of liver enzymes, and headache. Serious side effects may include risk of serious infections, blood clots, and changes in certain blood cell counts. -Upper respiratory tract infections, Nausea, Increased liver function tests, Platelet elevations, Acne, Herpes simplex infection, Low white blood cell count (neutropenia),thrombosis, Lymphoma and other malignancies
-Baricitinib may interact with certain medications, including live vaccines, biologic DMARDs, and certain antiviral drugs. It is important for healthcare providers to be aware of all medications a patient is taking to avoid potential interactions. -strong OAT3 inhibitors (such as probenecid)
